{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:23:16Z","timestamp":1788009796848,"version":"build-2784847793"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T00:00:00Z","timestamp":1684540800000},"content-version":"am","delay-in-days":292,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ajo.2022.03.018","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T02:53:48Z","timestamp":1647917628000},"page":"265-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Topical Pharmacologic Interventions Versus Active Control, Placebo, or No Treatment for Epidemic Keratoconjunctivitis: Findings From a Cochrane Systematic Review"],"prefix":"10.1016","volume":"240","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1151-7983","authenticated-orcid":false,"given":"Su-Hsun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara S.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sueko M.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genie","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9350-5478","authenticated-orcid":false,"given":"Irene C.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ajo.2022.03.018_bib0001","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0161-6420(89)32749-7","article-title":"Epidemiology and diagnosis of acute conjunctivitis at an inner-city hospital","volume":"96","author":"Fitch","year":"1989","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2022.03.018_bib0002","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/jmv.21175","article-title":"Monitoring of adenovirus from conjunctival scrapings in Japan during 2005\u20132006","volume":"80","author":"Matsui","year":"2008","journal-title":"J Med Virol"},{"issue":"5","key":"10.1016\/j.ajo.2022.03.018_bib0003","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/bjo.69.5.385","article-title":"Prevalence of chlamydial eye infection in patients attending an eye clinic, a VD clinic, and in healthy persons","volume":"69","author":"Ronnerstam","year":"1985","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2022.03.018_bib0004","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1001\/archopht.1982.01030040253009","article-title":"Laboratory studies in acute conjunctivitis","volume":"100","author":"Stenson","year":"1982","journal-title":"Archives of Ophthalmology"},{"key":"10.1016\/j.ajo.2022.03.018_bib0005","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/bjo.84.9.968","article-title":"Clinical and epidemiological features of acute follicular conjunctivitis with special reference to that caused by herpes simplex virus type 1","volume":"84","author":"Uchio","year":"2000","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2022.03.018_bib0006","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0035-9203(92)90328-A","article-title":"Causes of conjunctivitis and keratoconjunctivitis in Karachi, Pakistan","volume":"86","author":"Woodland","year":"1992","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"8","key":"10.1016\/j.ajo.2022.03.018_bib0007","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1185\/03007990903038269","article-title":"Acute conjunctivitis: truth and misconceptions","volume":"25","author":"O'Brien","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"10.1016\/j.ajo.2022.03.018_bib0008","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0022-3476(81)80754-8","article-title":"Etiology of acute conjunctivitis in children","volume":"98","author":"Gigliotti","year":"1981","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.ajo.2022.03.018_bib0009","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/ije\/16.1.98","article-title":"Comparative studies on aetiology and epidemiology of viral conjunctivitis in three countries of East Asia\u2014Japan","volume":"16","author":"Ishii","year":"1987","journal-title":"Int J Epidemiol"},{"issue":"6","key":"10.1016\/j.ajo.2022.03.018_bib0010","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/infdis\/160.6.938","article-title":"A large outbreak of epidemic keratoconjunctivitis: problems in controlling nosocomial spread","volume":"160","author":"Warren","year":"1989","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.ajo.2022.03.018_bib0011","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/archopht.1972.01000020260005","article-title":"Adenovirus type 8 infections in the United States. IV. Observations on the pathogenesis of lesions in severe eye disease","volume":"87","author":"Dawson","year":"1972","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2022.03.018_bib0012","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/01.ico.0000170693.13326.fb","article-title":"Adenoviral keratoconjunctivitis in a tertiary care eye clinic","volume":"25","author":"Butt","year":"2006","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.ajo.2022.03.018_bib0013","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/archopht.1970.00990040038010","article-title":"Corneal infiltrates in epidemic keratoconjunctivitis. Response to double-blind corticosteroid therapy","volume":"84","author":"Laibson","year":"1970","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2022.03.018_bib0014","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1001\/archopht.119.10.1487","article-title":"Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a controlled clinical pilot study","volume":"119","author":"Hillenkamp","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2022.03.018_bib0015","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0161-6420(02)00992-2","article-title":"The effects of cidofovir 1% with and without cyclosporin A 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study","volume":"109","author":"Hillenkamp","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2022.03.018_bib0016","first-page":"125","article-title":"Treatment of epidemic keratoconjunctivitis by human leukocyte interferon","volume":"24","author":"Negoro","year":"1980","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2022.03.018_bib0017","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1089\/jir.1980.1.95","article-title":"Use of human fibroblast-derived (beta) interferon in the treatment of epidemic adenovirus keratoconjunctivitis","volume":"1","author":"Romano","year":"1980","journal-title":"J Interferon Res"},{"issue":"3","key":"10.1016\/j.ajo.2022.03.018_bib0018","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF02215650","article-title":"The value of exogenous interferon in adenovirus keratoconjunctivitis. Preliminary results","volume":"218","author":"Sundmacher","year":"1982","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2022.03.018_bib0019","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1442-9071.2010.02457.x","article-title":"Anti-adenoviral effect of interferon-beta and interferon-gamma in serotypes that cause acute keratoconjunctivitis","volume":"39","author":"Uchio","year":"2011","journal-title":"Clin Exp Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2022.03.018_bib0020","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/ICO.0000000000001279","article-title":"Topical tacrolimus for corneal subepithelial infiltrates secondary to adenoviral keratoconjunctivitis","volume":"36","author":"Berisa Prado","year":"2017","journal-title":"Cornea"},{"key":"10.1016\/j.ajo.2022.03.018_bib0021","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/archopht.1996.01100130573014","article-title":"The effects of corticosteroids of adenoviral replication","volume":"114","author":"Romanowski","year":"1996","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2022.03.018_bib0022","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00003226-200108000-00020","article-title":"Short-term treatment with a potent topical corticosteroid of an acute ocular adenoviral infection in the New Zealand white rabbit","volume":"20","author":"Romanowski","year":"2001","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.ajo.2022.03.018_bib0023","article-title":"Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis","volume":"3","author":"Liu","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajo.2022.03.018_bib0024","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2022"},{"issue":"1","key":"10.1016\/j.ajo.2022.03.018_bib0025","article-title":"Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis","volume":"1","author":"Kuo","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajo.2022.03.018_bib0026","author":"Covidence [software]","year":"2021"},{"key":"10.1016\/j.ajo.2022.03.018_bib0027","author":"Review Manager (RevMan Web)","year":"2020"},{"key":"10.1016\/j.ajo.2022.03.018_bib0028","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ajo.2022.03.018_sbref0029","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"Chapter 10: Analysing data and undertaking meta-analyses","author":"Deeks","year":"2021"},{"key":"10.1016\/j.ajo.2022.03.018_sbref0031","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence","author":"Sch\u00fcnemann","year":"2022"},{"key":"10.1016\/j.ajo.2022.03.018_bib0031","first-page":"070","article-title":"Modified treatment for epidemic keratoconjunctivitis","volume":"7","author":"Elwan","year":"2020","journal-title":"J Ophthalmic Clin Res"},{"issue":"8","key":"10.1016\/j.ajo.2022.03.018_bib0032","doi-asserted-by":"crossref","first-page":"e686","DOI":"10.1111\/aos.13416","article-title":"Treatment of adenoviral keratoconjunctivitis with a combination of povidone-iodine 1.0% and dexamethasone 0.1% drops: a clinical prospective controlled randomized study","volume":"95","author":"Kovalyuk","year":"2017","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2022.03.018_bib0033","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10384-020-00788-3","article-title":"Comparative study of topical regimen for adenoviral kearoconjunctivitis by 0.1% fluorometholone with and without polyvinyl alcohol iodine","volume":"65","author":"Matsuura","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.ajo.2022.03.018_bib0034","first-page":"S579","article-title":"Ganciclovir effects in adenoviral keratoconjunctivitis [ARVO abstract 3111-B253]","volume":"42","author":"Tabbara","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.ajo.2022.03.018_bib0035","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/00003226-199305000-00006","article-title":"A prospective, masked clinical trial of trifluridine, dexamethasone, and artificial tears in the treatment of epidemic keratoconjunctivitis","volume":"12","author":"Ward","year":"1993","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.ajo.2022.03.018_bib0036","first-page":"98","article-title":"Comparison of topical steroid drops with cyclosporin eye drops in the treatment of corneal subepithelial infiltrates in epidemic keratoconjunctivitis","volume":"14","author":"Rafe","year":"2020","journal-title":"Pak J Med Health Sci"},{"issue":"5","key":"10.1016\/j.ajo.2022.03.018_bib0037","doi-asserted-by":"crossref","first-page":"594","DOI":"10.4103\/ijo.IJO_1352_18","article-title":"Comparison of the safety and efficacy of topical tacrolimus (0.03%) versus dexamethasone (0.05%) for subepithelial infiltrates after adenoviral conjunctivitis","volume":"67","author":"Bhargava","year":"2019","journal-title":"Indian J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2022.03.018_bib0038","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/ICO.0000000000002589","article-title":"Corticosteroids versus cyclosporine for subepithelial infiltrates secondary to epidemic keratoconjunctivitis: a prospective randomized double-blind study","volume":"40","author":"Gouider","year":"2021","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.ajo.2022.03.018_bib0039","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41433-020-01344-6","article-title":"Efficacy and tolerability of polyvinylpyrrolidone-iodine 0.6% treatment in adenoviral keratoconjunctivitis: a prospective randomized controlled study","volume":"36","author":"Ricciardelli","year":"2022","journal-title":"Eye (Lond)"},{"issue":"6","key":"10.1016\/j.ajo.2022.03.018_bib0040","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1055\/s-2008-1057579","article-title":"The effects of topical steroids in epidemic kerato-conjunctivitis (author's transl) [in German]","volume":"176","author":"Trauzettel-Klosinski","year":"1980","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1016\/j.ajo.2022.03.018_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2019.100826","article-title":"Mystery eye: human adenovirus and the enigma of epidemic keratoconjunctivitis","volume":"76","author":"Jonas","year":"2020","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ajo.2022.03.018_bib0042","doi-asserted-by":"crossref","unstructured":"Labib BA, Minhas BK, Chigbu DI. Management of Adenoviral Keratoconjunctivitis: Challenges and Solutions. Clinical Ophthalmology 2020;14:837-852.","DOI":"10.2147\/OPTH.S207976"},{"issue":"12","key":"10.1016\/j.ajo.2022.03.018_bib0043","doi-asserted-by":"crossref","first-page":"7171","DOI":"10.1128\/AAC.03860-14","article-title":"Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters","volume":"58","author":"Ying","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ajo.2022.03.018_bib0044","article-title":"Efficacy and safety of GV 550 in acute adenovirus keratoconjunctivitis","year":"2010","journal-title":"ClinicalTrials.gov identifier: NCT01156025"},{"issue":"6","key":"10.1016\/j.ajo.2022.03.018_bib0045","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1590\/S0004-27492011000600007","article-title":"Ganciclovir 0.15% ophthalmic gel in the treatment of adenovirus keratoconjunctivitis [in Portuguese]","volume":"74","author":"Yabiku","year":"2011","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.ajo.2022.03.018_bib0046","article-title":"A placebo controlled comparison of topical zirgan versus genteal gel for the treatment of adenovirus conjunctivitis","year":"2018","journal-title":"ClinicalTrails.gov identifier: NCT01533480"},{"key":"10.1016\/j.ajo.2022.03.018_bib0047","unstructured":"Study of the comparative efficacy of two different treatments used in acute conjunctivitis by adenovirus: ganciclovir 0.15% and saline solution 0.9%. World Health Organization International Clinical Trials Registry Search Platform identifier: EUCTR2014-002319-41-ES. Updated July 20, 2015. Accessed March 15, 2022. http:\/\/wwwwhoint\/trialsearch\/Trial2aspx?TrialID=EUCTR2014-002319-41-ES."},{"key":"10.1016\/j.ajo.2022.03.018_bib0048","article-title":"Evaluate the use of ganciclovir gel 0.3% for the treatment of conjunctivitis caused by adenovirus","year":"2012","journal-title":"ClinicalTrials.gov identifier: NCT02600365"},{"issue":"9","key":"10.1016\/j.ajo.2022.03.018_bib0049","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/jamaophthalmol.2017.2835","article-title":"Adenoviral conjunctivitis in health care settings: why accurate diagnosis and infection control matter","volume":"135","author":"Kuo","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2022.03.018_bib0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ajo.2015.12.007","article-title":"A polymerase chain reaction-based algorithm to detect and prevent transmission of adenoviral conjunctivitis in hospital employees","volume":"163","author":"Kuo","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2022.03.018_bib0051","unstructured":"Hogan MJ, Crawford JW. Epidemic keratoconjunctivitis (superficial punctate keratitis, keratitis subepithelialis, keratitis maculosa, keratitis nummularis) with a review of the literature and a report of 125 cases. Am J Ophthalmol 1942;25:1059-1078."},{"issue":"6","key":"10.1016\/j.ajo.2022.03.018_bib0052","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1056\/NEJM199408113310611","article-title":"The continuing unethical use of placebo controls","volume":"331","author":"Rothman","year":"1994","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ajo.2022.03.018_bib0053","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jamaophthalmol.2021.0150","article-title":"Cost savings from a policy to diagnose and prevent transmission of adenoviral conjunctivitis in employees of a large academic medical center","volume":"139","author":"Kuo","year":"2021","journal-title":"JAMA Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939422001180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939422001180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:51:51Z","timestamp":1757598711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939422001180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":53,"alternative-id":["S0002939422001180"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2022.03.018","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical Pharmacologic Interventions Versus Active Control, Placebo, or No Treatment for Epidemic Keratoconjunctivitis: Findings From a Cochrane Systematic Review","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2022.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}